Source Bioscience International provided laboratory services and products to the healthcare and clinical, life science research and biopharma industries. Services include diagnostic testing for cancer and other infectious disease, DNA sequencing and contract research activities, cryostorage and stability testing. Its product range include serology products for blood and tissue banking, life science research reagents and controlled environment chambers. Source BioScience operates ten facilities across the UK, Ireland and the US and has customers in over 90 countries. Source BioScience was an investment of Fund 4 from 2016 until its IPO in 2021.